|
Post by peppy on Mar 7, 2017 9:16:38 GMT -5
|
|
|
Post by goyocafe on Mar 7, 2017 9:20:54 GMT -5
I guess it doesn't take much at the moment. It's ALIVE!
|
|
|
Post by slugworth008 on Mar 7, 2017 9:30:17 GMT -5
Even the dumbest kid who wants to sell lemonade at the side of the road has enough sense to put up a sign and advertise. No advertisement no demand no sales. Well said ...slug what are we drinking!kball's suggestion... Anything. And everything. Maybe Matt should switch to the lemonade business. Sh-t this just reminded me of the DeSisto fiasco....so many of them...Yep I'm getting thirsty again.
|
|
|
Post by peppy on Mar 7, 2017 9:33:03 GMT -5
I guess it doesn't take much at the moment. It's ALIVE! hopefully we can take MNKD off the Jet ventilator, that is giving 300 breathes per min and put in on a regular positive pressure vent with high pressures. rate of 60 pressures 30 ccm h20 over 5. If we can ever extubate and put MNKD on c-pap, it will be a miracle.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 7, 2017 10:29:48 GMT -5
kball's suggestion... Anything. And everything. Maybe Matt should switch to the lemonade business. Sh-t this just reminded me of the DeSisto fiasco....so many of them...Yep I'm getting thirsty again. We are selling our lemonade from a position of strength
|
|
|
Post by cjm18 on Mar 7, 2017 10:37:46 GMT -5
Actually that indicates that Mannkind is 3.22 times as volatile as the market. Mannkind's r-squared is 3.17 which means that 3% of its moves can be explained by moves in the market. www.hedgeable.com/quote/MNKDSPY, an ETF, has an r-squared of 96.26%. www.hedgeable.com/quote/SPYIn other words Mannkind doesn't follow the market. Yes it depends on the definition of follow the market. If the market goes up one unit then Mnkd will go up 3.2. And vice versa. More volatile. More risk. The formula for beta is the correlation between stock and market returns multiplied by stocks standard deviation and then divided by markets s.d.
|
|
|
Post by slugworth008 on Mar 7, 2017 10:40:54 GMT -5
Maybe Matt should switch to the lemonade business. Sh-t this just reminded me of the DeSisto fiasco....so many of them...Yep I'm getting thirsty again. We are selling our lemonade from a position of strength LMFAO - Good one reverselo! The new "Epic Lemonade" sooo tasty.
|
|
|
Post by kc on Mar 7, 2017 10:54:56 GMT -5
I don't know about the lemonade but I do feel very squeezed.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Mar 7, 2017 11:52:28 GMT -5
We are selling our lemonade from a position of strength LMFAO - Good one reverselo! The new "Epic Lemonade" sooo tasty. Embarrassment of lemons......stay tuned
|
|
|
Post by dreamboatcruise on Mar 7, 2017 13:45:04 GMT -5
It would be nice if you had some technical analysis or historical data regarding reverse splits supporting this $1.3 low thesis. I think I'll just imagine you do rather than asking and risk disappointment Its just personal experience. IMO they tend to lose almost half their value. Then come right back up and hang out there until some good or bad news or earnings. I don't have a lot of experience with RS... or at least it's been too long to remember details. What do you think the probability that yesterday was the low based purely on RS vs future news?
|
|
|
Post by peppy on Mar 7, 2017 14:10:35 GMT -5
I guess it doesn't take much at the moment. It's ALIVE! hopefully we can take MNKD off the Jet ventilator, that is giving 300 breathes per min and put in on a regular positive pressure vent with high pressures. rate of 60 pressures 30 ccm h20 over 5. If we can ever extubate and put MNKD on c-pap, it will be a miracle.
The baby is nice and pink, reduce the vent pressures to 30 over 4.
|
|
|
Post by zuegirdor on Mar 7, 2017 14:20:36 GMT -5
Not that we should pretend everything is hunky dory but as I recall being said before, perhaps the strategy was to time advertising for when the team felt it had a grip on the nuance of dosing Afrezza. As many have no doubt discovered, it is not so straightforward. Afrezza is undeniably an important tool that should be in all diabetic's tool kits. but I am not sure that is the strongest praise: it implies a sort of conditional application.
I think most would like to believe Afrezza's strongest appeal is as a pateint's sole prandial insulin. There are many reason's why that may not be realistic for all. I am not saying that MNKD needs to base its ad campaign on anything other than a replacement for injected. Certainly a piecemeal approach to promoting it would seem like burying the "revolutionary breakthrough" lead that we have all been touting. But I wonder if there is a way to highlight all the ways Afrezza deserves a role in every diabetics self-treatment? No doubt a well funded and thought out ad campaign would be the way to do this. And a devil lives there....
But back to my premise on dosing. Advertising is not the best introduction to Afrezza in these early days. Its necessary to get the word out. But MNKD needs to acknowledge that users will need to be educated. And another devil lives there...
|
|
|
Post by kc on Mar 7, 2017 14:28:50 GMT -5
Its just personal experience. IMO they tend to lose almost half their value. Then come right back up and hang out there until some good or bad news or earnings. I don't have a lot of experience with RS... or at least it's been too long to remember details. What do you think the probability that yesterday was the low based purely on RS vs future news? I have shares in intuitive surgical that once had a reverse split is now trading at 732.00 per share.
|
|
|
Post by peppy on Mar 7, 2017 14:32:00 GMT -5
Not that we should pretend everything is hunky dory but as I recall being said before, perhaps the strategy was to time advertising for when the team felt it had a grip on the nuance of dosing Afrezza. As many have no doubt discovered, it is not so straightforward. Afrezza is undeniably an important tool that should be in all diabetic's tool kits. but I am not sure that is the strongest praise: it implies a sort of conditional application. I think most would like to believe Afrezza's strongest appeal is as a pateint's sole prandial insulin. There are many reason's why that may not be realistic for all. I am not saying that MNKD needs to base its ad campaign on anything other than a replacement for injected. Certainly a piecemeal approach to promoting it would seem like burying the "revolutionary breakthrough" lead that we have all been touting. But I wonder if there is a way to highlight all the ways Afrezza deserves a role in every diabetics self-treatment? No doubt a well funded and thought out ad campaign would be the way to do this. And a devil lives there.... But back to my premise on dosing. Advertising is not the best introduction to Afrezza in these early days. Its necessary to get the word out. But MNKD needs to acknowledge that users will need to be educated. And another devil lives there... The learning curve for fast acting mealtime insulin is larger. It is just very different. RAA blood glucose goes very high, then very low. Some diabetes take the insulin 1/2 hour before meals? They have to eat on time then. Or split the dose? or just go high then low, that seems to be the status quo gig. The one they are told is safer. Afrezza, keep blood glucose from going high in the first place. totally different management. Regarding using both and tool boxes. Tools are expensive. Most mechanics buy their own tools. Something would need to change in the insurance game. New legislation coming, insurance plans being gamed as we speak. I do not believe insurance will be cheaper when the gaming is done. Plenty of campaign contributions that need to be repaid.
|
|
|
Post by esstan2001 on Mar 7, 2017 14:39:32 GMT -5
LMFAO - Good one reverselo! The new "Epic Lemonade" sooo tasty. Embarrassment of lemons......stay tuned Now that was sour... very sour.
|
|